#1 Clinical Trials Search in Europe

Study on Dostarlimab to Prevent Second Cancer in Patients Cured from Primary Cancer

2 1 1 1

What is this study about?

This clinical trial is focused on patients who have been cured of a primary cancer and are at risk of developing a second cancer. The study is investigating the effects of a treatment called dostarlimab, also known by its code names WBP-285 and TSR-042. Dostarlimab is a medication that is given through an intravenous infusion, which means it is administered directly into the bloodstream through a vein. The purpose of the study is to determine if a short course of treatment with dostarlimab can reduce the risk of developing a second primary cancer after the initial cancer has been successfully treated.

Participants in the study will receive dostarlimab, which is provided as a concentrate for solution for infusion, meaning it is prepared as a liquid that is infused into the body. The study will compare the outcomes of those receiving dostarlimab with those who do not, to see if the medication can help prevent a second cancer from occurring. The study will be conducted over a period of time, and participants will be monitored for the development of any new cancers and their overall health status.

The trial aims to provide valuable information on whether dostarlimab can be an effective preventive treatment for patients who have already been treated for a primary cancer. By participating in this study, researchers hope to better understand the potential benefits of dostarlimab in reducing the risk of second primary cancers, ultimately improving the long-term health outcomes for cancer survivors.

1 joining the study

Upon joining the study, the patient will sign a written informed consent form. This form confirms understanding of the study and willingness to comply with study visits and procedures.

The patient must be at least 18 years old and have been cured of a primary cancer, with a risk of developing a second cancer.

2 initial assessment

The patient will undergo an initial assessment to confirm eligibility. This includes a review of medical history, current health status, and any risk factors for a second primary cancer.

A tumor sample from the prior cancer diagnosis will be required for comparison in case of new cancer development.

3 treatment with dostarlimab

The patient will receive treatment with dostarlimab, administered as an intravenous infusion. The specific dosage and frequency will be determined by the study protocol.

The treatment aims to assess whether a short course of dostarlimab reduces the risk of developing a second primary cancer.

4 follow-up visits

The patient will attend regular follow-up visits to monitor health status and any potential side effects of the treatment.

These visits will include physical examinations, laboratory tests, and possibly imaging studies to assess the occurrence of a second primary cancer.

5 completion of study

Upon completion of the study, the patient’s health will be evaluated to determine the impact of dostarlimab on the risk of developing a second primary cancer.

The study aims to provide valuable information on the effectiveness of dostarlimab in preventing second cancers in patients who have been cured of a primary cancer.

Who Can Join the Study?

  • Patient must be a male or female who is at least 18 years old.
  • Patient must have been cured from a primary cancer and be at risk of developing a second cancer.
  • Patient must have had 1 or 2 primary solid tumors that were treated with the intent to cure. The last cancer treatment must have ended less than 6 months before joining the study.
  • Patient must have at least one risk factor for a second cancer, such as:
    • Long-term tobacco use (more than 20 years).
    • Genetic predisposition, like mutations in genes such as p53 or BRCA, or conditions like Lynch syndrome.
    • Having a cancer related to HPV (Human Papillomavirus).
  • Patient must provide a sample of their previous tumor for comparison if a new cancer develops.
  • Patient must have a good performance status, meaning they are fully active or have some restrictions but can still carry out light work.
  • Patient must have adequate blood and organ function, as shown by specific laboratory test results.
  • Patient must have a corrected QT interval (a measure of heart rhythm) of less than 450 milliseconds, or less than 480 milliseconds if they have a specific heart condition called bundle branch block.
  • Women who can have children must have a negative pregnancy test and agree to use effective birth control during the study and for up to 6 months after the last dose of the study drug.
  • Men who are fertile must agree to use effective birth control during the study and for up to 6 months after the last dose of the study drug.
  • Patient must understand and sign a consent form before any study-specific procedures are done and be willing to follow the study requirements.
  • Patient must have medical insurance if it is required in their country.

Who Cannot Join the Study?

  • Patients who have not been cured from their primary cancer.
  • Patients who are not at risk of developing a second cancer.
  • Patients who are not within the specified age range for the study.
  • Patients who belong to a vulnerable population group.

Where you can join this trial?

Verified and Recommended Sites

No sites found in this category

Verified Sites

Site Name City Country Status
Centre Jean Perrin Clermont Ferrand France
Paris – Hôpital Cochin Paris France
Institut Gustave Roussy Villejuif France
Oncopole Claudius Regaud Toulouse France

Other Sites

Site Name City Country Status
Centre Antoine Lacassagne Nice France
Hopital Beaujon Clichy France
Institut de Cancérologie de l’Ouest Saint-Herblain France
Centre Francois Baclesse Caen France
Cgikvv Lilm Bfwydi Lyon France
Itkgpbkm Ckrtl Paris France

Want to learn more about this study or check if you can participate? Contact us.

Trial status

Country Status Recruitment Start
France France
Recruiting
16.01.2023

Trial locations

Investigated drugs:

Dostarlimab is a type of medication known as an immunotherapy. It works by helping your immune system recognize and attack cancer cells. In this clinical trial, dostarlimab is being tested to see if it can help prevent the development of a second primary cancer in patients who have already been treated for their first cancer. The goal is to see if a short course of this medication can reduce the risk of developing another cancer after the initial one has been cured.

Investigated diseases:

Second Primary Cancer – Second primary cancer refers to a new cancer that occurs in an individual who has previously been treated for another cancer. It is distinct from a recurrence or metastasis of the original cancer. The development of a second primary cancer can be influenced by genetic factors, environmental exposures, or the effects of previous cancer treatments. This condition progresses independently of the first cancer and requires separate evaluation and management. The risk of developing a second primary cancer varies depending on the type of the first cancer and the treatments received. Monitoring and regular follow-ups are essential to detect any new cancer early.

Trial ID:
2022-501316-34-00
Protocol code:
PREDOSTAR/ET22-215
NCT ID:
NCT05855811
Trial Phase:
Therapeutic exploratory (Phase II)

Other Trials to Consider

  • Study on the Safety and Effects of VERT-002 for Patients with Advanced Solid Tumors, Including Lung Cancer with MET Alterations

    Recruiting

    2 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium France Germany Italy The Netherlands Spain

  • Telisotuzumab Adizutecan for Locally Advanced or Metastatic Solid Tumors with MET Amplification in Patients 12 Years and Older

    Recruiting

    2 1 1
    Investigated diseases:
    Denmark France Spain